Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 2/20 | 0.53 |
| ▸ | PIK3CA | P42336 | 16/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12485526 | 0.87 | IGF1R (0.43) | IGF1RPIK3CAKDM4ESMN1; SMN2HSD17B10 | |
| Hydrochloric Acid SCHEMBL17698286 | 0.86 | IGF1R (0.43) | IGF1RPIK3CAKDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL12484478 | 0.81 | MAPT (0.57) | PIK3CAKDM4ESMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL17698366 | 0.80 | MAPT (0.56) | PIK3CAKDM4ESMN1; SMN2 | |
| SCHEMBL12486541 | 0.80 | PIK3C3 (0.39) | IGF1RPIK3CAKDM4ENPC1SMN1; SMN2 | |
| SCHEMBL12486207 | 0.80 | PIK3C3 (0.41) | IGF1RPIK3CA | |
| SCHEMBL12484578 | 0.79 | BCL6 (0.41) | IGF1RPIK3CAKDM4ENPC1SMN1; SMN2 | |
| SCHEMBL12484569 | 0.79 | BCL6 (0.41) | IGF1RPIK3CAKDM4ENPC1SMN1; SMN2 | |
| SCHEMBL881132 | 0.79 | PIK3CA (0.70) | IGF1RPIK3CA | |
| SCHEMBL12485520 | 0.79 | MTOR (0.59) | PIK3CANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10640490-B2 | Diaminopyrimidine derivatives and processes for the preparation thereof | YUHAN CORPORATION (KR) | 2020-05-05 | — | — | US | claimed |
| US-20180072705-A1 | DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2018-03-15 | — | — | US | claimed |
| US-9850227-B2 | Diaminopyrimidine derivatives and processes for the preparation thereof | YUHAN CORPORATION (KR) | 2017-12-26 | — | — | US | claimed |
| EP-2678331-B1 | DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORP (KR) | 2016-04-27 | — | — | EP | claimed |
| EP-2678331-A2 | DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | Yuhan Corporation (KR) | 2014-01-01 | — | — | EP | claimed |
| US-20130331377-A1 | DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2013-12-12 | — | — | US | claimed |
| WO-2012115478-A2 | DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2012-08-30 | — | — | WO | claimed |
| US-10640490-B2 | Diaminopyrimidine derivatives and processes for the preparation thereof | YUHAN CORPORATION (KR) | 2020-05-05 | — | — | US | disclosed |
| US-20180072705-A1 | DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2018-03-15 | — | — | US | disclosed |
| US-9850227-B2 | Diaminopyrimidine derivatives and processes for the preparation thereof | YUHAN CORPORATION (KR) | 2017-12-26 | — | — | US | disclosed |
| EP-2678331-B1 | DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORP (KR) | 2016-04-27 | — | — | EP | disclosed |
| EP-2678331-A2 | DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | Yuhan Corporation (KR) | 2014-01-01 | — | — | EP | disclosed |
| US-20130331377-A1 | DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2013-12-12 | — | — | US | disclosed |
| WO-2012115478-A2 | DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2012-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331377-A1 | DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | HRH2, GIPR, SSTR4 | IGF1R 1920/4885PIK3CA 796/4885KDM4E 3532/4885 |
| US-10640490-B2 | Diaminopyrimidine derivatives and processes for the preparation thereof | HRH2, GIPR, SSTR4 | IGF1R 1920/4885PIK3CA 796/4885KDM4E 3532/4885 |
| US-20180072705-A1 | DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | HRH2, GIPR, SSTR4 | IGF1R 1920/4885PIK3CA 796/4885KDM4E 3532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.